Oral Cancer

P=N/A, N=60, Recruiting, Virginia Commonwealth University | Trial completion date: Jan 2026 --> Oct 2026 | Trial primary completion date: Jan 2026 --> Oct 2026

SNHG26 depletion reversed NK cell suppression and cisplatin resistance in vitro and in vivo. Thus, our study identifies exosomal SNHG26 as a key mediator of cisplatin resistance and NK cell dysfunction in TSCC, suggesting its potential as a promising therapeutic target.

Oral melanocytic neoplasms are rare and have distinct clinicopathological features. Despite this, a gap exists in molecular data regarding ODN and AMP. Conversely, OMN and OMM have distinct profiles; in particular, the latter may benefit modestly from tyrosine kinase inhibitor treatment, as KIT and BRAF mutations are sensitive to imatinib and vemurafenib, respectively.

P=N/A, N=167, Completed, Centre Hospitalier Universitaire de Besancon | Recruiting --> Completed | N=240 --> 167 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

Thus, BMI1 expression leads to increases in key features of early-stage, carcinogen-induced tumorigenesis, including metabolic reprogramming. Consequently, limiting BMI1 could be a potential target for cancer prevention approaches that merits further consideration and additional functional studies.

An EGR1+ neutrophil transcriptional signature predicted poor clinical outcomes across multiple cancer types. These findings identify EGR1 as a hypoxia-inducible driver of neutrophil-mediated immunosuppression and provide a basis for targeting the hypoxia-EGR1 axis to overcome immunotherapy resistance.

A similar reactivity to that from primary tumors was also noticed in metastatic LN proliferations. So, we concluded that these three biomarkers are involved in OSCC progression and dissemination and their investigation may have prognostic and therapeutic utility.

HLA-B*35:359 differs from HLA-B*35:01:01:01 by one nucleotide substitution at position 650 (C → T) in exon 4.

SYPL1 is significantly upregulated in OSCC tissues and shows potential as a diagnostic biomarker for distinguishing tumours from normal samples, particularly in early detection. Elevated SYPL1 expression is associated with poor prognosis in patients with OSCC, especially in T3 and N0 stages, suggesting that it could complement the TNM staging system for improved risk stratification. Mechanistically, the negative correlation between SYPL1 expression and infiltrating cytotoxic and dendritic cells implies a possible role in immune modulation, but this requires functional validation. Future studies should focus on elucidating the functional mechanisms of SYPL1 to assess its therapeutic relevance.

P1/2, N=242, Recruiting, VM Oncology, LLC | Phase classification: P1 --> P1/2 | N=82 --> 242 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027

Additionally, we explore the potential of targeting these molecules to enhance the efficacy of radiation therapy and improve patient outcomes. Our study contributes to the comprehension of the molecular processes underlying oral cancer and provides insights into the development of novel therapeutic strategies based on personalized medicine.

Moringa's diverse mechanisms, broad-spectrum activity, and low toxicity underscore its potential as an adjunct in cancer therapy. Future research should focus on clinical validation, standardized formulations, delivery systems, understudied cancers, and combinatorial regimens with conventional therapies to advance its role in integrative oncology.